Navigation Links
InterMune Announces Presentations of New Research in IPF at ERS
Date:8/27/2012

ith Idiopathic Pulmonary Fibrosis Receiving Commonly Used Concomitant Medications"
Location: Hall A11/P718

Monday, September 3, 2012
14:45 - 16:45 h
Oral Presentation
Dr. Ulrich Costabel:  "Analysis of Lung Function and Survival in RECAP: An Open-label Extension Study of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis"
Location: Oral Presentation OP2820/Hall A3

Tuesday, September 4, 2012
08:30 - 10:30 h
Poster Discussion
Dr. Dominique Valeyre:  "The Long-term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis: Integrated Analysis of Safety from Four Clinical Trials"
Location: Hall A5/P3159

12:50 - 14:40 h
Poster Presentation
Dr. Steve Nathan:  "6-Minute Walk Test in Patients with Idiopathic Pulmonary Fibrosis: Confirmation of the Minimal Clinically Important Difference"
Location: Hall A13/P3656

About RECAP
RECAP is an open-label extension study for patients who participated in the Phase 3 program for Esbriet, known as CAPACITY.  The CAPACITY program (studies 004 and 006) was designed to evaluate the safety and efficacy of Esbriet in IPF patients with mild to moderate impairment in lung function. In the CAPACITY studies, 779 patients were randomized to treatment with Esbriet or placebo and 626 patients completed the study.  Of these, 603 (96 percent) were enrolled in RECAP. 

Long-term safety results from RECAP were initially presented at the Annual Congress of the European Respiratory Society (ERS) in September 2011.  These results demonstrated that long-term treatment with Esbriet was safe and generally well-tolerated, with a long-term safety profile similar to that observed in CAPACITY.

About Esbriet® (pirfenidone)
Esbriet is an orally active drug that inhibits the synthesis of TGF-beta, a chemical mediator that controls many cell functions including proliferation
'/>"/>

SOURCE InterMune, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. InterMune to Divest Actimmune® (Interferon Gamma-1b)
2. InterMune Reports Second Quarter 2012 Financial Results and Business Highlights
3. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
4. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
5. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
6. Misonix Announces New Distribution Agreement For Panama
7. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
8. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
9. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
10. Soligenix Announces Further Progress with ThermoVax™ for Long-Term Vaccine ThermoStability
11. Masimo Announces New Low-Profile Infant and Neonatal Pulse Oximetry Sensors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014  Humberto C. Antunes,  Galderma  worldwide CEO, will receive ... Journal of Drugs in Dermatology (JDD) at the ... event is January 17-20, 2014, at the Omni Orlando Resort at ... The ODAC is a distinguished event that delivers ...
(Date:1/15/2014)... 2014 MultiCell Technologies, Inc. (OTC Bulletin Board: ... application concerning composition of matter, biological targets, mechanism of ... death.  This patent application describes a ... molecules (VSRNAs) which interfere with the basic homeostatic cellular ...
(Date:1/15/2014)... 15, 2014 Reportlinker.com announces that a ... its catalogue: PharmaPoint: ... Market Analysis to 2022 ... - India Drug Forecast and Market Analysis ...
Breaking Medicine Technology:Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5
... Financial Highlights f or the ... : Revenues increased 58.1% to $24.2 million ... Net income rose 73.6% to $13.4 million, representing a net margin of 55.5% ... " ) increased to $0.80; Diluted EPS increased to $0.79 ...
... EMERYVILLE, Calif., March 28, 2011 Bionovo, Inc. (Nasdaq: ... and development of safe and effective treatments for women,s health ... Phase 1 clinical trial testing the safety of two doses ... hot flushes (study # MF101-008), also known as "menopausal hot ...
Cached Medicine Technology:Nutrastar Announces Record 2010 Performance and Revenue Guidance for 2011 2Nutrastar Announces Record 2010 Performance and Revenue Guidance for 2011 3Nutrastar Announces Record 2010 Performance and Revenue Guidance for 2011 4Nutrastar Announces Record 2010 Performance and Revenue Guidance for 2011 5Nutrastar Announces Record 2010 Performance and Revenue Guidance for 2011 6Nutrastar Announces Record 2010 Performance and Revenue Guidance for 2011 7Nutrastar Announces Record 2010 Performance and Revenue Guidance for 2011 8Nutrastar Announces Record 2010 Performance and Revenue Guidance for 2011 9Bionovo Announces Enrollment Started in the Menerba (MF101) Phase 1 "Tolerability" Clinical Trial for Menopausal Hot Flushes 2Bionovo Announces Enrollment Started in the Menerba (MF101) Phase 1 "Tolerability" Clinical Trial for Menopausal Hot Flushes 3
(Date:7/9/2014)... that sudden, acute episodes of low back pain are ... air pressure, wind direction and precipitation. Findings published in ... the American College of Rheumatology (ACR), indicate that the ... wind speed or wind gusts, but was not clinically ... (WHO) nearly everyone experiences low back pain at some ...
(Date:7/9/2014)... Susan Wakulich was told she had an aneurysm, she figured ... her. , "I was devastated," said Wakulich, who is 56 ... this was a serious diagnosis. Then I met Dr. Bernard ... a less invasive procedure. It was something I didn,t even ... a multi-center U.S. clinical trial to evaluate the safety and ...
(Date:7/9/2014)... into the metabolism of stromal support cells and immune ... these cell types in the development of diseases ... and cancer. That was the conclusion of a review ... the leading journal Nature . , Prof. Peter ... call. The metabolism of cancer cells has been examined ...
(Date:7/9/2014)... from The Miriam Hospital have found that people ... also depressed have difficulty sticking to a pulmonary ... for women, and screening and brief treatment of ... The study and its findings are published in ... Chronic obstructive pulmonary disease is a common and ...
(Date:7/9/2014)... Montefiore Medical Center and the Albert ... present new findings at the Alzheimer,s Association International Conference ... Copenhagen, Denmark. Data from the four abstracts will focus ... to mild cognitive impairment and dementia. The research is ... in 1980 to examine healthy brain aging as well ...
Breaking Medicine News(10 mins):Health News:Low back pain? Don't blame the weather 2Health News:New type of stent could help some brain aneurysm patients 2Health News:Wake-up call for more research into cell metabolism 2Health News:Miriam Hospital study examines effect of depressed mood on pulmonary rehab completion 2Health News:Investigators from Montefiore and Einstein to present data at 2014 Alzheimer's Association International Conference 2Health News:Investigators from Montefiore and Einstein to present data at 2014 Alzheimer's Association International Conference 3
... of Nationwide Awareness Campaign - KENILWORTH, N.J., March ... SGP ), maker of the non-drowsy ... allergy sufferer and NASCAR driver Carl Edwards to ... News Release, go to: http://www.prnewswire.com/mnr/claritin/37512/ "Drowsy driving ...
... DENVER, March 18 St. Joseph,s Hospital in Marshfield, ... Medical Technologies, VersaRad CR radiography system. These units ... as for St. Joe,s Diagnostic Imaging services. St. Joseph,s ... of the Marshfield medical complex serving Wisconsin and the ...
... Northern California Chapter of the National MS SocietyMOUNTAIN VIEW, Calif., ... special donation program to coincide with MS Awareness ... a cure for multiple sclerosis. For each sale of a ... 2009, Presto Services Inc. will donate 5% of the retail ...
... TO ARMS 2009 EDITION" is a new documentary ... traces the controversial Anthrax Vaccine Immunization Program ( AVIP ... Through the personal invitation of Rick and Rozene ... Baristo Rd., Palm Springs, CA, the documentary feature had ...
... equipment to be acquired as part of purchaseMOUNTAIN VIEW, ... Los Gatos Town Council last evening, El Camino Hospital ... Camino Hospital had signed agreements that will allow an ... Los Gatos acquisition. The agreements will allow El ...
... March 17 Standard & Poor,s Rating Services (S&P) ... ,B, on Huntsman Corporation,s (NYSE: HUN ) ... that its operations are sound and that its liquidity ... Huntsman has met the challenging operating environment by ...
Cached Medicine News:Health News:Video: CLARITIN Partners with NASCAR Driver Carl Edwards to Educate Motorists on the Importance of Being Clear to Drive(SM) 2Health News:Video: CLARITIN Partners with NASCAR Driver Carl Edwards to Educate Motorists on the Importance of Being Clear to Drive(SM) 3Health News:Fischer Medical Announces Multi-System VersaRad Installation at St. Joseph's Hospital in Marshfield, WI 2Health News:Presto Announces Donation Program to Help Find the Cure for Multiple Sclerosis 2Health News:Presto Announces Donation Program to Help Find the Cure for Multiple Sclerosis 3Health News:Scott Miller and Company Premieres "A CALL TO ARMS 2009 EDITION" at the Camelot Theaters in Palm Springs 2Health News:Scott Miller and Company Premieres "A CALL TO ARMS 2009 EDITION" at the Camelot Theaters in Palm Springs 3Health News:Scott Miller and Company Premieres "A CALL TO ARMS 2009 EDITION" at the Camelot Theaters in Palm Springs 4Health News:Scott Miller and Company Premieres "A CALL TO ARMS 2009 EDITION" at the Camelot Theaters in Palm Springs 5Health News:Scott Miller and Company Premieres "A CALL TO ARMS 2009 EDITION" at the Camelot Theaters in Palm Springs 6Health News:Scott Miller and Company Premieres "A CALL TO ARMS 2009 EDITION" at the Camelot Theaters in Palm Springs 7Health News:Scott Miller and Company Premieres "A CALL TO ARMS 2009 EDITION" at the Camelot Theaters in Palm Springs 8Health News:Scott Miller and Company Premieres "A CALL TO ARMS 2009 EDITION" at the Camelot Theaters in Palm Springs 9Health News:Scott Miller and Company Premieres "A CALL TO ARMS 2009 EDITION" at the Camelot Theaters in Palm Springs 10Health News:Parties in Los Gatos Hospital Acquisition Agree on Terms Allowing El Camino Hospital an Early Close of Escrow 2Health News:Parties in Los Gatos Hospital Acquisition Agree on Terms Allowing El Camino Hospital an Early Close of Escrow 3Health News:Huntsman Responds to S&P Action 2Health News:Huntsman Responds to S&P Action 3
... Coagulation tubes contain a ... is available with a citrate ... or 0.129 mol/l (3.8%). The ... citrate solution to 9 parts ...
Plastic Citrate Tube, .109M / 3.2%...
VACUETTE paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients....
VACUETTE paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients....
Medicine Products: